Blog Buzz: January 29 – February 3

Posted on by

Another week of big waves out on the blogs and Twitter…

The rumble about open access, the proposed Research Works Act and a growing boycott of Elsevier by some academics continues in a few related items: As Journal Boycott Grows, Elsevier Defends Its Practices, reports the Chronicle of Higher Education (via @Mandosally); KraftyLibrarian asks if a boycott of Elsevier can really be successful in the biomedical field in Elsevier Boycott, My Thoughts; and in a post that  begins with Monty Python but is serious, David Dobbs asks, Is the Open Science Revolution for Real?

The NY Times reported on the Uproar as Komen Foundation Cuts Money to Planned Parenthood and the Atlantic said Top Susan G. Komen Official Resigned Over Planned Parenthood Cave-in. Now, after a week of impassioned public debate, Komen has reversed its decision.

There are proposals in both houses for legislative changes to the FDA.  Here are reports on how increased funding could speed discovery and approval of new drugs and ease drug shortages.

And just for fun this week, a fifth grader has discovered a new molecule and been published and there is a free collection of silhouettes of organisms called PhyloPic!

MSKCC in the News: January 26 – February 8

Posted on by
  • MSKCC’s Howard Scher presented findings for the investigational oral drug MDV3100 at the 2012 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium.
  • Dr. Monica Morrow of MSKCC was quoted in a New York Times article about a study that examined the outcomes of breast cancer surgeries in women from four institutions and three health plans.
  • MSKCC researchers reported that a scale used to measure bone metastases has been found useful in determining whether some prostate cancer patients are responding to chemotherapy. The study was published in the Journal of Clinical Oncology.